1
|
Whelan K, Mertens A, Castleberry R, Mitby P, Kawashima T, Sklar C, Packer R, Waterbor J, Blatt J, Robison L. Visual complications in childhood cancer survivors: A Childhood Cancer Survivor Study report. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.9006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9006 Background: The Childhood Cancer Survivor Study (CCSS) is an NIH funded project (U01-CA 55727) designed to study the effects of childhood cancer treatment on long- term survivors. Previous studies have found associations between certain cancer therapies and visual complications. Methods: The CCSS is a retrospective cohort study investigating health outcomes of long-term survivors (> 5 years) diagnosed and treated between 1970 and 1986 compared to a randomly selected sibling cohort. Questionnaires were completed by 14,362 survivors of childhood cancer and 3,901 sibling controls. Analysis determined the first occurrence of 8 visual conditions in 3 time periods: during therapy, end of therapy to 5 years post diagnosis, and greater than or equal to 5 years post diagnosis. Multivariate analyses, adjusting for current age and gender, determined the relative risks (RR) and 95% confidence interval (CI) of visual conditions by treatment exposure. Results: Survivors had statistically significant increases in the RR of cataracts, glaucoma, legal blindness, double vision, retinal condition, and dry eyes, across all time periods, when compared to siblings. During the time period of 5 or more years post-diagnosis, statistically significant positive associations were present for cataracts and other head radiation, craniospinal radiation, total body radiation, and prednisone; glaucoma and craniospinal radiation; double vision and craniospinal radiation; legally blind and other head radiation and craniospinal radiation; and dry eyes and other head radiation, total body radiation, and dexamethasone. There were no statistically significant associations between treatment factors and retinal conditions. Conclusions: Childhood cancer survivors are at risk of developing visual complications and treatment related factors are important determinants of this risk. Follow-up is needed to evaluate the impact of visual conditions on quality of life. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Whelan
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; Memorial Sloan-Kettering Cancer Center, New York, NY; Children’s National Medical Center, Washington D.C., DC; University of North Carolina, Chapel Hill, NC; St. Jude’s Children’s Reseach Hospital, Memphis, TN
| | - A. Mertens
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; Memorial Sloan-Kettering Cancer Center, New York, NY; Children’s National Medical Center, Washington D.C., DC; University of North Carolina, Chapel Hill, NC; St. Jude’s Children’s Reseach Hospital, Memphis, TN
| | - R. Castleberry
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; Memorial Sloan-Kettering Cancer Center, New York, NY; Children’s National Medical Center, Washington D.C., DC; University of North Carolina, Chapel Hill, NC; St. Jude’s Children’s Reseach Hospital, Memphis, TN
| | - P. Mitby
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; Memorial Sloan-Kettering Cancer Center, New York, NY; Children’s National Medical Center, Washington D.C., DC; University of North Carolina, Chapel Hill, NC; St. Jude’s Children’s Reseach Hospital, Memphis, TN
| | - T. Kawashima
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; Memorial Sloan-Kettering Cancer Center, New York, NY; Children’s National Medical Center, Washington D.C., DC; University of North Carolina, Chapel Hill, NC; St. Jude’s Children’s Reseach Hospital, Memphis, TN
| | - C. Sklar
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; Memorial Sloan-Kettering Cancer Center, New York, NY; Children’s National Medical Center, Washington D.C., DC; University of North Carolina, Chapel Hill, NC; St. Jude’s Children’s Reseach Hospital, Memphis, TN
| | - R. Packer
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; Memorial Sloan-Kettering Cancer Center, New York, NY; Children’s National Medical Center, Washington D.C., DC; University of North Carolina, Chapel Hill, NC; St. Jude’s Children’s Reseach Hospital, Memphis, TN
| | - J. Waterbor
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; Memorial Sloan-Kettering Cancer Center, New York, NY; Children’s National Medical Center, Washington D.C., DC; University of North Carolina, Chapel Hill, NC; St. Jude’s Children’s Reseach Hospital, Memphis, TN
| | - J. Blatt
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; Memorial Sloan-Kettering Cancer Center, New York, NY; Children’s National Medical Center, Washington D.C., DC; University of North Carolina, Chapel Hill, NC; St. Jude’s Children’s Reseach Hospital, Memphis, TN
| | - L. Robison
- University of Alabama at Birmingham, Birmingham, AL; University of Minnesota, Minneapolis, MN; Fred Hutchinson Cancer Research Center, Seattle, WA; Memorial Sloan-Kettering Cancer Center, New York, NY; Children’s National Medical Center, Washington D.C., DC; University of North Carolina, Chapel Hill, NC; St. Jude’s Children’s Reseach Hospital, Memphis, TN
| |
Collapse
|
3
|
Malogolowkin MH, Katzenstein H, Krailo M, Bowman L, Reynolds M, Finegold M, Greffe B, Rowland J, Newman K, Castleberry R. Intensive versus standard platinum therapy for the treatment of children with hepatoblastoma (HB): A report of the Intergroup Hepatoblastoma Study P9645. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.8516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. H. Malogolowkin
- Childrens Hospital Los Angeles Keck School of Medicine, USC, Los Angeles, CA; Children's Oncology Group, Arcadia, CA
| | - H. Katzenstein
- Childrens Hospital Los Angeles Keck School of Medicine, USC, Los Angeles, CA; Children's Oncology Group, Arcadia, CA
| | - M. Krailo
- Childrens Hospital Los Angeles Keck School of Medicine, USC, Los Angeles, CA; Children's Oncology Group, Arcadia, CA
| | - L. Bowman
- Childrens Hospital Los Angeles Keck School of Medicine, USC, Los Angeles, CA; Children's Oncology Group, Arcadia, CA
| | - M. Reynolds
- Childrens Hospital Los Angeles Keck School of Medicine, USC, Los Angeles, CA; Children's Oncology Group, Arcadia, CA
| | - M. Finegold
- Childrens Hospital Los Angeles Keck School of Medicine, USC, Los Angeles, CA; Children's Oncology Group, Arcadia, CA
| | - B. Greffe
- Childrens Hospital Los Angeles Keck School of Medicine, USC, Los Angeles, CA; Children's Oncology Group, Arcadia, CA
| | - J. Rowland
- Childrens Hospital Los Angeles Keck School of Medicine, USC, Los Angeles, CA; Children's Oncology Group, Arcadia, CA
| | - K. Newman
- Childrens Hospital Los Angeles Keck School of Medicine, USC, Los Angeles, CA; Children's Oncology Group, Arcadia, CA
| | - R. Castleberry
- Childrens Hospital Los Angeles Keck School of Medicine, USC, Los Angeles, CA; Children's Oncology Group, Arcadia, CA
| |
Collapse
|
7
|
Nitschke R, Smith EI, Altshuler G, Altmiller D, Shuster J, Green A, Castleberry R, Hayes FA, Golembe B, Ducos R. Postoperative treatment of nonmetastatic visible residual neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991; 9:1181-8. [PMID: 2045858 DOI: 10.1200/jco.1991.9.7.1181] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
The Pediatric Oncology Group (POG) evaluated in a prospective study the hypothesis that patients who had localized, visible residual neuroblastoma without regional lymph node involvement after surgery (POG stage B) have a favorable prognosis when treated with moderate intensive chemotherapy. Eligible patients were initially treated with five courses of Cytoxan (cyclophosphamide; Bristol-Myers Squibb Co., Evansville, IN) and Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH) followed by surgery (CY/AD +/- surgery). Those patients not achieving a complete remission (CR) crossed over to five courses of cisplatin and teniposide (PL/VM) +/- surgery. Radiation therapy (XRT) was given to selected patients who still were not in CR after the crossover therapy. Of the 61 eligible patients, 38 (62%) patients achieved CR after CY/AD proven by clinical (31) or surgical (seven) evaluation. One (2%) patient in clinical partial remission (PR-C) entered CR without further therapy. Nineteen (31%) patients achieved CR with the following salvage therapies: surgery (five), PL/VM +/- surgery (five) followed by XRT (three) or autologous bone marrow transplant (ABMT) (one) and further courses of CY/AD +/- PL/VM instead of courses of PL/VM (five). The overall CR rate was 95% (58 of 61). Four patients had recurrence of the disease. The probability of being disease-free at 3 years after initial or salvage therapy was estimated at 84% (SE, 5%). The overall prognosis of children older than 1 year and younger than 1 year was similar (P = .26). If, however, the three remission deaths (all younger than 1 year) were censored, there was only one other failure in 32 children younger than one versus seven of 29 children older than 1 year (P = .018). These results confirm the excellent prognosis for patients with POG stage B neuroblastoma and indicate that most patients are curable with CY/AD +/- surgery, and those not achieving CR with this therapy are curable with alternate therapy.
Collapse
Affiliation(s)
- R Nitschke
- Oklahoma University Health Sciences Center, Oklahoma City
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Borzillo GV, Cooper MD, Bertoli LF, Landay A, Castleberry R, Burrows PD. Lineage and stage specificity of isotype switching in humans. The Journal of Immunology 1988. [DOI: 10.4049/jimmunol.141.10.3625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Abstract
The lineage and stage specificity of human isotype switch recombination was investigated by examining the IgH gene configuration in 61 hemopoietic malignancies representing different stages of B and T cell development. An unexpectedly high frequency (20%) of IgM-producing B cell leukemias and lymphomas had undergone CH gene rearrangements and deletions consistent with attempted switch recombination. These CH gene alterations were found on productive, non-productive, and 14q+ chromosomes. These data support the concept of a non-specific (common) switch recombinase activity that is often ineffective. No evidence of such switch recombination was found in 25 mu- or mu+ pre-B cell leukemias with the single exception of a mu- pre-B leukemia in which subsets of the cells were producing gamma- or alpha-H chains. The switch recombinase activity gamma- or alpha-H chains. The switch recombinase activity may be restricted to the B cell lineage, inasmuch as CH gene deletions were not observed in T lineage malignancies.
Collapse
Affiliation(s)
- G V Borzillo
- Department of Pediatrics, University of Alabama, Birmingham 35294
| | - M D Cooper
- Department of Pediatrics, University of Alabama, Birmingham 35294
| | - L F Bertoli
- Department of Pediatrics, University of Alabama, Birmingham 35294
| | - A Landay
- Department of Pediatrics, University of Alabama, Birmingham 35294
| | - R Castleberry
- Department of Pediatrics, University of Alabama, Birmingham 35294
| | - P D Burrows
- Department of Pediatrics, University of Alabama, Birmingham 35294
| |
Collapse
|